Mr. Fabbio has more than 25 years of financial, operational and transactional leadership experience in both publicly-traded and privately-held life science and pharmaceutical companies. Prior to joining WindMIL, Mr. Fabbio was Executive Vice President and Chief Financial Officer of Progenics Pharmaceuticals Inc. Previously he served as the Chief Financial Officer of electroCore Medical, LLC, where he developed the corporate finance strategy and led additional financing in preparation for FDA approval and launch. Mr. Fabbio was also Vice President of Finance for NPS Pharmaceuticals, Inc.; Vice President of Finance, Innovation and Growth at Catalent Pharma Solutions Inc.; and Chief Financial Officer at Ikano Therapeutics. His other prior financial positions include roles at Sanofi, UniPath Diagnostics, BioMatrix and Coopers & Lybrand. Mr. Fabbio graduated from Pace University with a BBA in Accounting, received his MBA from the Stern School of Business at New York University and is a Certified Public Accountant.
Mr. Fabbio leads development and execution of the company’s financial strategy and partners with WindMIL’s senior leadership team to provide insight and recommendations for the achievement of both short and long term company goals. Mr. Fabbio is responsible for WindMIL’s financial analysis, budget, forecast, cash management, accounting and tax operations.